References
1. Antonicelli L, Bilo MB, Bonifazi F. Epidemiology of Hymenoptera allergy. Curr Opin Allergy Clin Immunol. 2002;2(4):341-346.
2. Golden DB, Marsh DG, Kagey-Sobotka A, et al. Epidemiology of insect venom sensitivity. Jama. 1989;262(2):240-244.
3. Bilo BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis.Curr Opin Allergy Clin Immunol. 2008;8(4):330-337.
4. Bokanovic D, Aberer W, Griesbacher A, Sturm GJ. Prevalence of hymenoptera venom allergy and poor adherence to immunotherapy in Austria. Allergy. 2011;66(10):1395-1396.
5. Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy.2018;73(4):744-764.
6. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.J Allergy Clin Immunol. 1992;89(2):529-535.
7. Rueff F, Vos B, Elberink JO, et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy. 2014;44(5):736-746.
8. Rueff F, Przybilla B, Bilo MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124(5):1047-1054.
9. Arzt L, Bokanovic D, Schwarz I, et al. Hymenoptera stings in the head region induce impressive, but not severe sting reactions.Allergy. 2016;71(11):1632-1634.
10. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol. 2012;130(3):698-704 e691.
11. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet.2001;357(9253):361-362.
12. Rueff F, Przybilla B, Bilo MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol. 2010;126(1):105-111 e105.
13. Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.J Allergy Clin Immunol. 2002;110(6):928-933.
14. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. Jama.2013;310(9):959-968.
15. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data.Lancet. 2005;365(9455):217-223.
16. Brown SG. Clinical features and severity grading of anaphylaxis.J Allergy Clin Immunol. 2004;114(2):371-376.
17. Nassiri M, Babina M, Dolle S, Edenharter G, Rueff F, Worm M. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol.2015;135(2):491-499.
18. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466-469.
19. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy. 2005;60(11):1339-1349.
20. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.Allergy. 2005;60(12):1459-1470.
21. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw. 2015;67(1):48.
22. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):67.
23. Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol. 1990;86(3 Pt 1):407-411.
24. Muller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol.2005;115(3):606-610.
25. Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clin Exp Allergy.2014;44(5):747-755.
26. Carlson GS, Wong PH, White KM, Quinn JM. Evaluation of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy in immunotherapy-associated systemic reactions. J Allergy Clin Immunol Pract. 2017;5(5):1430-1432.
27. Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective. Ann Allergy Asthma Immunol. 2015;114(5):411-416.
28. Tejedor-Alonso MA, Farias-Aquino E, Pérez-Fernández E, Grifol-Clar E, Moro-Moro M, Rosado-Ingelmo A. Relationship Between Anaphylaxis and Use of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies. J Allergy Clin Immunol Pract. 2019;7(3):879-897.e875.
29. Lang DM. Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf. 1995;12(5):299-304.
30. White JL, Greger KC, Lee S, et al. Patients Taking β-Blockers Do Not Require Increased Doses of Epinephrine for Anaphylaxis. J Allergy Clin Immunol Pract. 2018;6(5):1553-1558.e1551.
31. Rueff F, Przybilla B, Bilo MB, et al. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PLoS One.2013;8(5):e63233.